{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-23-001212","form_type":"8-K","ticker":"TEVA","cik":"0000818686","company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","filed_at":"2023-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.723018+00:00","generated_at":"2026-06-12T15:44:14.226166+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Teva Q2 2023 revenue $3.88B, GAAP loss $0.77/sh, non-GAAP EPS $0.56; raises revenue guidance","bullets":["Revenue $3.88B (+2% YoY, +4% local currency); AUSTEDO U.S. rev $308M.","GAAP net loss $863M ($0.77 loss per share) vs $232M loss in Q2 2022.","Non-GAAP diluted EPS $0.56, down from $0.68 YoY; non-GAAP operating margin 26.1%.","Free cash flow $632M; operating cash flow $324M.","FY 2023 revenue guidance raised to $15.0-$15.4B; all other guidance reaffirmed."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-23-001212","json":"https://secwatch.observer/filing/0001157523-23-001212.json","markdown":"https://secwatch.observer/filing/0001157523-23-001212.md","text":"https://secwatch.observer/filing/0001157523-23-001212.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818686/000115752323001212/0001157523-23-001212-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818686/000115752323001212/a53501990.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T15:44:14.226166+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b79b8690b5cc840f1929e872b68cdfd15041cfcb","claim":"TEVA PHARMACEUTICAL INDUSTRIES LTD reported the quarter ended June 30, 2023 results: revenue $3,878 million, EPS GAAP loss per share of $0.77 Non-GAAP diluted EPS of $0.56. Guidance reaffirmed.","evidence_excerpt":"structure, while also reorganizing key business units to enhance operational efficiency. Second Quarter 2023 Consolidated Results Revenues in the second quarter of 2023 were $3,878 million, an increase of 2% compared to the second quarter of 2022. In local currency terms, revenues increased by 4%, mainly due to higher revenues from AUSTEDO and Anda in our North","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/818686/000115752323001212/0001157523-23-001212-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Revenue","value":"$3,878 million"},{"label":"EPS","value":"GAAP loss per share of $0.77 Non-GAAP diluted EPS of $0.56"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}